Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The researchers examined the effect of calcitriol versus cholecalciferol supplementation on vascular endothelial function in patients with CKD.

Who Took Part

The abstract describes 128 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The primary end point was change in brachial artery flow-mediated dilation.

Secondary end points included changes in circulating markers of mineral metabolism and circulating and cellular markers of inflammation.

What Was Measured

PubMed files the paper under topics including Biomarkers, Brachial Artery, Calcitriol, Cholecalciferol, Colorado, Dietary Supplements and Glomerular Filtration Rate.

Author keywords: 25-hydroxyvitamin D, Adult, Calcifediol, Dilatation, Double-Blind Method and Humans.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 128 patients.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.